Discovery of Brivanib Alaninate: A Dual Vascular Endothelial Growth Factor and Fibroblast Growth Factor Receptor Inhibitor

Kinase Inhibitor Drugs

Volumn , Issue , 2009, Pages 131-166

  Bhide, Rajeev S ^a   Fargnoli, Joseph ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Brivanib alaninate discovery; Dynamic contrast enhanced magnetic resonance imaging (DCE MRI); VEGFR2 kinase domain

Indexed keywords

EID: 84889837960     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470524961.ch6     Document Type: Chapter

References (77)

1. Aiello, L. P., Pierce, E. A., Foley, E. D., et al. (1995). Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Nat Acad Sci. 92 (23), 10457-10461.
2. Ayers, M., Fargnoli, J., Lewin, A., et al. (2007). Discovery and validation of biomarkers that respond to treatment with brivanib alaninate, a small-molecule VEGFR-2/FGFR-1 antagonist. Cancer Res. 67 (14), 6899-6906.
3. Baluk, P., Morikawa, S., Haskell, A., et al. (2003). Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors. Am J Pathol. 163 (5), 1801-1815.
4. Barker, A. J., Gibson, K. H., Grundy, W., et al. (2001). Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorg Med Chem Lett. 11 (14), 1911-1914.
5. Bastaki, M., Nelli, E. E., Dell'Era, P., et al. (1997). Basic fibroblast growth factor -induced angiogenic phenotype in mouse endothelium: a study of aortic and microvascular endothelial cell lines. Arterioscler Thromb Vasc Biol. 17 (3), 454-464.
6. Benjamin, L. E., Golijanin, D., Itin, A., et al. (1999). Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest. 103 (2), 159-165.
7. Bhide, R. S., Cai, Z. W., Zhang, Y. Z., et al. (2006). Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1 H-indol-5-yloxy)-5-methylpyrrolo[2,1-f ][1,2,4] triazin-6-yloxy)propan-2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor . J Med Chem. 49 (7), 2143-2146.
8. Borzilleri, R. M., Cai, Z. W., Ellis, C., et al. (2005a). Synthesis and SAR of 4-(3 -hydroxyphenylamino)pyrrolo[2,1-f ][1,2,4]triazine based VEGFR-2 kinase inhibitors . Bioorg Med Chem Lett. 15, 1429-1433.
9. Borzilleri, R. M., Zheng, X., Qian, L., et al. (2005b). Design, synthesis, and evaluation of orally active 4-(2,4-difluoro-5-(methoxycarbamoyl)phenylamino)pyrrolo[2,1-f ] [1,2,4]triazines as dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 inhibitors. J Med Chem. 48 (12), 3991-4008.
10. Cai, Z. W., Zhang, Y. Z., Borzilleri, R. M., et al. (2008). Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1 H-indol-5-yloxy)-5-methylpyrrolo[2,1-f ][1,2,4] triazin-6-yloxy)propan-2-yl) 2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215). J Med Chem. 51 (6), 1976-1980.
11. Carmeliet, P., and Jain, R. K. (2000). Angiogenesis in cancer and other diseases. Nature. 407 (6801), 249-257.
12. Casanovas, O., Hicklin, D. J., Bergers, G., et al. (2005). Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell. 8 (4), 299-309.
13. Cristofanilli, M., Charnsangavej, C., and Hortobagyi, G. N. (2002). Angiogenesis modulation in cancer research: novel clinical approaches. Nat Rev Drug Discov. 1 (6), 415-426.
14. Dell'Era, P., Belleri, M., Stabile, H., et al. (2001). Paracrine and autocrine effects of fibroblast growth factor-4 in endothelial cells. Oncogene. 20 (21), 2655-2663.
15. Drevs, J., Hofmann, I., Hugenschmidt, H., et al. (2000). Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model. Cancer Res. 60 (17), 4819-4824.
16. Ferrara, N., and Davis-Smyth, T. (1997). The biology of vascular endothelial growth factor. Endocr Rev. 18 (1), 4-25.
17. Ferrara, N., and Kerbel, R. S. (2005). Angiogenesis as a therapeutic target. Nature. 438 (7070), 967-974.
18. Folkman, J. (1971). Tumor angiogenesis: therapeutic implications. N Engl J Med. 285 (21), 1182-1186.
19. Folkman, J., and Klagsbrun, M. (1987). Angiogenic factors. Science. 235 (4787), 442-447.
20. Fong, T. A., Shawver, L. K., Sun, L., et al. (1999). SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res. 59 (1), 99-106.
21. Fujisawa, H., Kurrer, M., Reis, R. M., et al. (1999). Acquisition of the glioblastoma phenotype during astrocytoma progression is associated with loss of heterozygosity on 10q25-qter. Am J Pathol. 155 (2), 387-394.
22. Galbraith, S. M., Maxwell, R. J., Lodge, M. A., et al. (2003). Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol. 21 (15), 2831-2842.
23. Garrett, C., Siu, L., El-Khoueiry, A., et al. (2008). A Phase I study of brivanib alaninate (BMS-582664), an oral dual inhibitor of VEGFR and FGFR tyrosine kinases, in combination with full dose cetuximab (BC) in patients (pts) with advanced gastrointestinal malignancies (AGM) who failed prior therapy. J Clin Oncol. 26 (May supplement), Abstract 4111.
24. Giavazzi, R., Giuliani, R., Coltrini, D., et al. (2001). Modulation of tumor angiogenesis by conditional expression of fibroblast growth factor-2 affects early but not established tumors. Cancer Res. 61 (1), 309-317.
25. Giavazzi, R., Sennino, B., Coltrini, D., et al. (2003). Distinct role of fibroblast growth factor-2 and vascular endothelial growth factor on tumor growth and angiogenesis. Am J Pathol. 162 (6), 1913-1926.
26. Gille, H., Kowalski, J., Yu, L., et al. (2000). A repressor sequence in the juxtamembrane domain of Flt-1 (VEGFR-1) constitutively inhibits vascular endothelial growth factor-dependent phosphatidylinositol 3 ′-kinase activation and endothelial cell migration. EMBO J. 19 (15), 4064-4073.
27. Glinksy, G. V., Glinskii, A. B., Stephenson, A. J., et al. (2004). Gene expression profiling predicts clinical outcome of prostate cancer. J Clin Invest. 113 (6), 913-923.
28. Godfrey, J. D., Hynes, J., et al. (2003). Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors. US patent application 2,003,186,982.
29. Griffioen, A. W., and Molema, G. (2000). Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation . Pharmacol Rev. 52 (2), 237-268.
30. Grose, R., and Dickson, C. (2005). Fibroblast growth factor signaling in tumorigenesis. Cytokine Growth Factor Rev. 16 (2), 179-186.
31. Grose, R., Fantl, V., Werner, S., et al. (2007). The role of fibroblast growth factor receptor 2b in skin homeostasis and cancer development. EMBO J. 26 (5), 1268-1278.
32. Gullino, P. M. (1978). Angiogenesis and oncogenesis. J Natl Cancer Inst. 61 (3), 639-643.
33. Hanahan, D., and Folkman, J. (1996). Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 86 (3), 353-364.
34. Hazan, R. B., Phillips, G. R., Qiao, R. F., et al. (2000). Exogenous expression of N-cadherin in breast cancer cells induces cell migration, invasion, and metastasis. J Cell Biol. 148 (4), 779-790.
35. Hennequin, L. F., Stokes, E. S. E., Thomas, A. P., et al. (2002). Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors. J Med Chem. 45 (6), 1300-1312.
36. Hiratsuka, S., Maru, Y., Okada, A., et al. (2001). Involvement of flt-1 tyrosine kinase (vascular endothelial growth factor receptor-1) in pathological angiogenesis. Cancer Res. 61 (3), 1207-1213.
37. Hunt, J. T., Mitt, T., Borzilleri, R., et al. (2004). Discovery of the pyrrolo[2,1-f ] [1,2,4]triazine nucleus as a new kinase inhibitor template. J Med Chem. 47 (16), 4054-4059.
38. Javerzat, S., Auguste, P., and Bikfalvi, A. (2002). The role of fibroblast growth factors in vascular development. Trends Mol Med. 8 (10), 483-489.
39. Jayson, G. C., Zweit, J., Jackson, A., et al. (2002). Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies. J Natl Cancer Inst. 94 (19), 1484-1493.
40. Jonker, D., Rosen, L. S., Sawyer, M., et al. (2007). A Phase I study of BMS-582664 (brivanib alaninate), an oral dual inhibitor of VEGFR and FGFR tyrosine kinases, in patients (pts) with advanced/metastatic solid tumors: safety, pharmacokinetic (PK), and pharmacodynamic (PD) findings. J Clin Oncol. 25 (18 S), 152S [Abstract 3559].
41. Kabalka, G. W., Reddy, N. K., and Narayana, C. (1993). Sodium perborate: a convenient reagent for benzylic hydroperoxide rearrangement. Tetrahedron Lett. 34, 7667-7668.
42. Kalluri, R. (2003). Basement membranes: structure, assembly and role in tumour angiogenesis. Nat Rev Cancer. 3 (6), 422-433.
43. Karashima, T., Inoue, K., Fukata, S., et al. (2007). Blockade of the vascular endothelial growth factor-receptor 2 pathway inhibits the growth of human renal cell carcinoma, RBM1-IT4, in the kidney but not in the bone of nude mice. Int J Oncol. 30 (4), 937-945.
44. Katoh, M., and Katoh, M. (2006). FGF signaling network in the gastrointestinal tract (review). Int J Oncol. 29 (1), 163-168.
45. Kerbel, R. S. (2000). Tumor angiogenesis: past, present and the near future. Carcinogenesis . 21 (3), 505-515.
46. Kerbel, R., and Folkman, J. (2002). Clinical translation of angiogenesis inhibitors. Nat Rev Cancer. 2 (10), 727-739.
47. Kerbel, R. S., Yu, J., Tran, J., et al. (2001). Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches. Cancer Metastasis Rev. 20, 79-86.
48. Kim, K. J., Li, B., Winer, J., et al. (1993). Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 362 (6423), 841-844.
49. Kondo, T., Zheng, L., Liu, W., et al. (2007). Epigenetically controlled fibroblast growth factor receptor 2 signaling imposes on the RAS/BRAF/mitogen-activated protein kinase pathway to modulate thyroid cancer progression. Cancer Res. 67 (11), 5461-5470.
50. Korpelainen, E. I., and Alitalo, K. (1998). Signaling angiogenesis and lymphangiogenesis . Curr Opin Cell Biol. 10 (2), 159-164.
51. Leenders, W. P. J., Kusters, B., Verrijp, K., et al. (2004). Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor progression via vessel co-option. Clin Cancer Res. 10 (18), 6222-6230.
52. Malone, H., Pictroski, C., Kukral, D., et al. (2005). Dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) tumor microcirculation studies in tumor bearing mice treated with VEGFR inhibitor BMS-582664. Proc Am Assoc Cancer Res. 46, 911-912.
53. Mancuso, M. R., Davis, R., Norberg, S. M., et al. (2006). Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest. 116 (10), 2610-2621.
54. Miller, K. D., Sweeney, C. J., and Sledge, G. W. Jr. (2003). The Snark is a Boojum: the continuing problem of drug resistance in the antiangiogenic era. Ann Oncol. 14, 20-28.
55. Miller, K. D., Sweeney, C. J., and Sledge, G. W. Jr. (2005). Can tumor angiogenesis be inhibited without resistance? EXS. 94, 95-112.
56. Motzer, R. J., Michaelson, M. D., Redman, B. G., et al. (2006). Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet - derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol. 24 (1), 16-24.
57. Moyer, J. D., Barbacci, E. G., Iwata, K. K., et al. (1997). Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res. 57 (21), 4838-4848.
58. Naimi, B., Latil, A., Fournier, G., et al. (2002). Down-regulation of (IIIb) and (IIIc) isoforms of fibroblast growth factor receptor 2 (FGFR2) is associated with malignant progression in human prostate. Prostate. 52 (3), 245-252.
59. Neufeld, G., Cohen, T., Gengrinovitch, S., et al. (1999). Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 13 (1), 9-22.
60. Nissen, L. J., Cao, R., Hedlund, E. M., et al. (2007). Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis . J Clin Invest. 117 (10), 2766-2777.
61. Pereg, D., and Lisher, M. (2008). Bevacizumab treatment for cancer patients with cardiovascular disease: a double edged sword? Eur Heart J., doi:10.1093/eurheartj/ehn384.
62. Purifoy, D. J. M., Beauchamp, L., De Miranda, M., et al. (1993). Review of research leading to new anti-herpesvirus agents in clinical development: valaciclovir hydrochloride (256u, the l-valyl ester of acyclovir) and 882c, a specific agent for varicella zoster virus. J Med Virol Suppl. 1, 139-145.
63. Ramanujan, S., Koenig, G. C., Padera, T. P., et al. (2000). Local imbalance of proangiogenic and antiangiogenic factors: a potential mechanism of focal necrosis and dormancy in tumors. Cancer Res. 60 (5), 1442-1448.
64. Rosen, L. S., Wilding, G., Sweeney, C. J., et al. (2006). Phase I dose escalation study to determine the safety, pharmacokinetics and pharmacodynamics of BMS-582664, a VEGFR/FGFR inhibitor in patients with advanced/metastatic solid tumors. J Clin Oncol. 24(18S), Abstract 3051.
65. Seghezzi, G., Patel, S., Ren, C. J., et al. (1998). Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: an autocrine mechanism contributing to angiogenesis. J Cell Biol. 141 (7), 1659-1673.
66. Shing, Y., Folkman, J., Sullivan, R., et al. (1984). Heparin affinity: purification of a tumor-derived capillary endothelial cell growth factor. Science. 223 (4642), 1296-1299.
67. Shipp, M. A., Ross, K. N., Tamayo, P., et al. (2002). Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med. 8 (1), 68-74.
68. Shojaei, F., Wu, X., Malik, A. K., et al. (2007). Tumor refractoriness to anti-VEGF treatment is mediated by CD11b + Gr1 + myeloid cells. Nat Biotechnol. 25 (8), 911-920.
69. Takahashi, J. A., Igarashi, K., Oda, K., et al. (1992). Correlation of basic fibroblast growth factor expression levels with the degree of malignancy and vascularity in human gliomas. J Neurosurg. 76 (5), 792-798.
70. Tille, J. C., Wood, J., Mandriota, S. J., et al. (2001). Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF-and basic fibroblast growth factor -induced angiogenesis in vivo and in vitro. J Pharmacol Exp Ther. 299 (3), 1073-1085.
71. 't Veer, L. J., Dai, H., van de Vijver, M., J., et al. (2002). Gene expression profiling predicts clinical outcome of breast cancer. Nature. 415 (6871), 530-536.
72. Vairaktaris, E., Ragos, V., Yapijakis, C., et al. (2006). FGFR-2 and-3 play an important role in initial stages of oral oncogenesis. Anticancer Res. 26 (6B), 4217-4221.
73. Wedge, S. R., Ogilvie, D., J., Dukes, M., et al. (2002). ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res. 62 (16), 4645-4655.
74. Wedge, S. R., Kendrew, J., Hennequin, L. F., et al. (2005). AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res. 65 (10), 4389-4400.
75. Willett, C. G., Boucher, Y., Duda, D. G., et al. (2005). Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a Phase I trial in rectal cancer patients. J Clin Oncol. 23 (31), 8136-8139.
76. Witte, L., Hicklin, D. J., Zhu, Z., et al. (1998). Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy. Cancer Metastasis Rev. 17 (2), 155-161.
77. Zittermann, S. I., and Issekutz, A. C. (2006). Basic fibroblast growth factor (bFGF, FGF-2) potentiates leukocyte recruitment to inflammation by enhancing endothelial adhesion molecule expression. Am J Pathol. 168 (3), 835-846.